摘要
子宮肌瘤為生育年齡婦女最常見的疾病，發生率大約為50%，症狀為經痛、經血過多、不孕等，而有上述症狀的婦女往往需要接受治療-包括藥物、非手術侵入性處置和手術。有症狀的肌瘤，又有生育計劃或個人考量的婦女，保留子宮而僅切除肌瘤是常執行的治療之一。在研究報告中，肌瘤切除手術後又復發肌瘤的5年累積機率為62%，其中超過30%的病人需要接受再次的介入性手術治療，但是先前的肌瘤切除手術往往併發子宮、腸道或骨盆的沾黏，使得再次介入性手術治療變得困難而且風險高。目前治療復發性子宮肌瘤的考量，以處理症狀（經痛、經血過多）、生育計劃或是術後併發症為原則，並非發現復發子宮肌瘤就必須再次手術治療。
參考文獻
1. Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinaryincontinence and bladder outlet obstruction. BJU Int 2011;108:1132-8.
3. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, activecontrolled phase 3 study to assess 12-month safety and efficacy of mirabegron, a b3-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296-305.
4. Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 2017;120:562-575.
5. Drake MJ, Chapple C, Esen AA, et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol 2016;70:136-45.
6. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol 2017;35:827-38.